APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Industry Research

Long-acting Insulin Injection Industry Research Report 2026

23 December 2025139 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Injection Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Injection Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Injection Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Injection Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Long-acting Insulin Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Long-acting Insulin Injection include United Laboratories, Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly & Co, Gan & Lee, Wockhardt, Viatris and Swixx Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Long-acting Insulin Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Long-acting Insulin Injection Market by Company

United Laboratories

Tonghua Dongbao

Sanofi

Novo Nordisk

Eli Lilly & Co

Gan & Lee

Wockhardt

Viatris

Swixx Biopharma

Lupin Laboratories

KALBE PHARMA

INFION PHARMA

Cipla

Biocon Biologics

Biocare

Abbott Laboratories

Long-acting Insulin Injection Segment by Type

Insulin Glargine

Insulin Detemir

Insulin Degludec

Long-acting Insulin Injection Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Long-acting Insulin Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Long-acting Insulin Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Long-acting Insulin Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Long-acting Insulin Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-acting Insulin Injection Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Long-acting Insulin Injection Sales (k units) of Manufacturers (2021-2026) Table 7. Global Long-acting Insulin Injection Sales Market Share by Manufacturers (2021-2026) Table 8. Global Long-acting Insulin Injection Revenue of Manufacturers (2021-2026) Table 9. Global Long-acting Insulin Injection Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Long-acting Insulin Injection Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Long-acting Insulin Injection Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Long-acting Insulin Injection, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Long-acting Insulin Injection, Product Type & Application Table 14. Global Long-acting Insulin Injection Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Long-acting Insulin Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. United Laboratories Company Information Table 19. United Laboratories Business Overview Table 20. United Laboratories Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. United Laboratories Long-acting Insulin Injection Product Portfolio Table 22. United Laboratories Recent Developments Table 23. Tonghua Dongbao Company Information Table 24. Tonghua Dongbao Business Overview Table 25. Tonghua Dongbao Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Tonghua Dongbao Long-acting Insulin Injection Product Portfolio Table 27. Tonghua Dongbao Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Sanofi Long-acting Insulin Injection Product Portfolio Table 32. Sanofi Recent Developments Table 33. Novo Nordisk Company Information Table 34. Novo Nordisk Business Overview Table 35. Novo Nordisk Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Novo Nordisk Long-acting Insulin Injection Product Portfolio Table 37. Novo Nordisk Recent Developments Table 38. Eli Lilly & Co Company Information Table 39. Eli Lilly & Co Business Overview Table 40. Eli Lilly & Co Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Eli Lilly & Co Long-acting Insulin Injection Product Portfolio Table 42. Eli Lilly & Co Recent Developments Table 43. Gan & Lee Company Information Table 44. Gan & Lee Business Overview Table 45. Gan & Lee Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Gan & Lee Long-acting Insulin Injection Product Portfolio Table 47. Gan & Lee Recent Developments Table 48. Wockhardt Company Information Table 49. Wockhardt Business Overview Table 50. Wockhardt Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Wockhardt Long-acting Insulin Injection Product Portfolio Table 52. Wockhardt Recent Developments Table 53. Viatris Company Information Table 54. Viatris Business Overview Table 55. Viatris Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Viatris Long-acting Insulin Injection Product Portfolio Table 57. Viatris Recent Developments Table 58. Swixx Biopharma Company Information Table 59. Swixx Biopharma Business Overview Table 60. Swixx Biopharma Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Swixx Biopharma Long-acting Insulin Injection Product Portfolio Table 62. Swixx Biopharma Recent Developments Table 63. Lupin Laboratories Company Information Table 64. Lupin Laboratories Business Overview Table 65. Lupin Laboratories Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Lupin Laboratories Long-acting Insulin Injection Product Portfolio Table 67. Lupin Laboratories Recent Developments Table 68. KALBE PHARMA Company Information Table 69. KALBE PHARMA Business Overview Table 70. KALBE PHARMA Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. KALBE PHARMA Long-acting Insulin Injection Product Portfolio Table 72. KALBE PHARMA Recent Developments Table 73. INFION PHARMA Company Information Table 74. INFION PHARMA Business Overview Table 75. INFION PHARMA Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. INFION PHARMA Long-acting Insulin Injection Product Portfolio Table 77. INFION PHARMA Recent Developments Table 78. Cipla Company Information Table 79. Cipla Business Overview Table 80. Cipla Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Cipla Long-acting Insulin Injection Product Portfolio Table 82. Cipla Recent Developments Table 83. Biocon Biologics Company Information Table 84. Biocon Biologics Business Overview Table 85. Biocon Biologics Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Biocon Biologics Long-acting Insulin Injection Product Portfolio Table 87. Biocon Biologics Recent Developments Table 88. Biocare Company Information Table 89. Biocare Business Overview Table 90. Biocare Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Biocare Long-acting Insulin Injection Product Portfolio Table 92. Biocare Recent Developments Table 93. Abbott Laboratories Company Information Table 94. Abbott Laboratories Business Overview Table 95. Abbott Laboratories Long-acting Insulin Injection Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Abbott Laboratories Long-acting Insulin Injection Product Portfolio Table 97. Abbott Laboratories Recent Developments Table 98. Global Long-acting Insulin Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Long-acting Insulin Injection Sales by Region (2021-2026) & (k units) Table 100. Global Long-acting Insulin Injection Sales Market Share by Region (2021-2026) Table 101. Global Long-acting Insulin Injection Sales by Region (2027-2032) & (k units) Table 102. Global Long-acting Insulin Injection Sales Market Share by Region (2027-2032) Table 103. Global Long-acting Insulin Injection Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Long-acting Insulin Injection Revenue Market Share by Region (2021-2026) Table 105. Global Long-acting Insulin Injection Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Long-acting Insulin Injection Revenue Market Share by Region (2027-2032) Table 107. North America Long-acting Insulin Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 109. North America Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 110. North America Long-acting Insulin Injection Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Long-acting Insulin Injection Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Long-acting Insulin Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 114. Europe Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 115. Europe Long-acting Insulin Injection Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Long-acting Insulin Injection Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Long-acting Insulin Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific Long-acting Insulin Injection Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Long-acting Insulin Injection Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Long-acting Insulin Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 124. South America Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 125. South America Long-acting Insulin Injection Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Long-acting Insulin Injection Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Long-acting Insulin Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa Long-acting Insulin Injection Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Long-acting Insulin Injection Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Long-acting Insulin Injection Sales by Type (2021-2026) & (k units) Table 133. Global Long-acting Insulin Injection Sales by Type (2027-2032) & (k units) Table 134. Global Long-acting Insulin Injection Sales Market Share by Type (2021-2026) Table 135. Global Long-acting Insulin Injection Sales Market Share by Type (2027-2032) Table 136. Global Long-acting Insulin Injection Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Long-acting Insulin Injection Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2026) Table 139. Global Long-acting Insulin Injection Revenue Market Share by Type (2027-2032) Table 140. Global Long-acting Insulin Injection Price by Type (2021-2026) & (USD/unit) Table 141. Global Long-acting Insulin Injection Price by Type (2027-2032) & (USD/unit) Table 142. Global Long-acting Insulin Injection Sales by Application (2021-2026) & (k units) Table 143. Global Long-acting Insulin Injection Sales by Application (2027-2032) & (k units) Table 144. Global Long-acting Insulin Injection Sales Market Share by Application (2021-2026) Table 145. Global Long-acting Insulin Injection Sales Market Share by Application (2027-2032) Table 146. Global Long-acting Insulin Injection Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Long-acting Insulin Injection Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2026) Table 149. Global Long-acting Insulin Injection Revenue Market Share by Application (2027-2032) Table 150. Global Long-acting Insulin Injection Price by Application (2021-2026) & (USD/unit) Table 151. Global Long-acting Insulin Injection Price by Application (2027-2032) & (USD/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Long-acting Insulin Injection Distributors List Table 155. Long-acting Insulin Injection Customers List Table 156. Long-acting Insulin Injection Industry Trends Table 157. Long-acting Insulin Injection Industry Drivers Table 158. Long-acting Insulin Injection Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Long-acting Insulin Injection Product Image Figure 5. Global Long-acting Insulin Injection Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Long-acting Insulin Injection Market Size (2021-2032) & (US$ Million) Figure 7. Global Long-acting Insulin Injection Sales (2021-2032) & (k units) Figure 8. Global Long-acting Insulin Injection Average Price (USD/unit) & (2021-2032) Figure 9. Insulin Glargine Product Image Figure 10. Insulin Detemir Product Image Figure 11. Insulin Degludec Product Image Figure 12. Type 1 Diabetes Product Image Figure 13. Type 2 Diabetes Product Image Figure 14. Global Long-acting Insulin Injection Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Long-acting Insulin Injection, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Long-acting Insulin Injection Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Long-acting Insulin Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Long-acting Insulin Injection Sales by Region in 2025 Figure 20. Global Long-acting Insulin Injection Revenue by Region in 2025 Figure 21. North America Long-acting Insulin Injection Market Size by Country in 2025 Figure 22. North America Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 23. North America Long-acting Insulin Injection Revenue Market Share by Country (2021-2032) Figure 24. United States Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Long-acting Insulin Injection Market Size by Country in 2025 Figure 28. Europe Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 29. Europe Long-acting Insulin Injection Revenue Market Share by Country (2021-2032) Figure 30. Germany Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Long-acting Insulin Injection Market Size by Country in 2025 Figure 41. Asia Pacific Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Long-acting Insulin Injection Revenue Market Share by Country (2021-2032) Figure 43. China Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Long-acting Insulin Injection Market Size by Country in 2025 Figure 52. South America Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 53. South America Long-acting Insulin Injection Revenue Market Share by Country (2021-2032) Figure 54. Brazil Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Long-acting Insulin Injection Market Size by Country in 2025 Figure 58. Middle East and Africa Long-acting Insulin Injection Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Long-acting Insulin Injection Revenue Market Share by Country (2021-2032) Figure 60. Egypt Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Long-acting Insulin Injection Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Long-acting Insulin Injection Sales Market Share by Type (2021-2032) Figure 66. Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2032) Figure 67. Global Long-acting Insulin Injection Price (USD/unit) by Type (2021-2032) Figure 68. Global Long-acting Insulin Injection Sales Market Share by Application (2021-2032) Figure 69. Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2032) Figure 70. Global Long-acting Insulin Injection Price (USD/unit) by Application (2021-2032) Figure 71. Long-acting Insulin Injection Value Chain Figure 72. Long-acting Insulin Injection Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Long-acting Insulin Injection Industry Opportunities and Challenges

Scope & coverage.

Types
  • Insulin Glargine
  • Insulin Detemir
  • Insulin Degludec
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
Companies covered
  • United Laboratories
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Eli Lilly & Co
  • Gan & Lee
  • Wockhardt
  • Viatris
  • Swixx Biopharma
  • Lupin Laboratories
  • KALBE PHARMA
  • INFION PHARMA
  • Cipla
  • Biocon Biologics
  • Biocare
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Long-acting Insulin Injection Market Size (2021-2032)
  4. 2.2.2 Global Long-acting Insulin Injection Sales (2021-2032)
  5. 2.2.3 Global Long-acting Insulin Injection Market Average Price (2021-2032)
  6. 2.3 Long-acting Insulin Injection by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Insulin Glargine
  9. 2.3.3 Insulin Detemir
  10. 2.3.4 Insulin Degludec
  11. 2.4 Long-acting Insulin Injection by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Type 1 Diabetes
  14. 2.4.3 Type 2 Diabetes
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Long-acting Insulin Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Long-acting Insulin Injection Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Insulin Injection Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Insulin Injection Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Long-acting Insulin Injection Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Long-acting Insulin Injection, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Long-acting Insulin Injection, Product Type & Application
  8. 3.8 Global Manufacturers of Long-acting Insulin Injection, Established Date
  9. 3.9 Global Long-acting Insulin Injection Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 United Laboratories
  2. 4.1.1 United Laboratories Company Information
  3. 4.1.2 United Laboratories Business Overview
  4. 4.1.3 United Laboratories Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 United Laboratories Long-acting Insulin Injection Product Portfolio
  6. 4.1.5 United Laboratories Recent Developments
  7. 4.2 Tonghua Dongbao
  8. 4.2.1 Tonghua Dongbao Company Information
  9. 4.2.2 Tonghua Dongbao Business Overview
  10. 4.2.3 Tonghua Dongbao Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Tonghua Dongbao Long-acting Insulin Injection Product Portfolio
  12. 4.2.5 Tonghua Dongbao Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Long-acting Insulin Injection Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Novo Nordisk
  20. 4.4.1 Novo Nordisk Company Information
  21. 4.4.2 Novo Nordisk Business Overview
  22. 4.4.3 Novo Nordisk Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novo Nordisk Long-acting Insulin Injection Product Portfolio
  24. 4.4.5 Novo Nordisk Recent Developments
  25. 4.5 Eli Lilly & Co
  26. 4.5.1 Eli Lilly & Co Company Information
  27. 4.5.2 Eli Lilly & Co Business Overview
  28. 4.5.3 Eli Lilly & Co Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly & Co Long-acting Insulin Injection Product Portfolio
  30. 4.5.5 Eli Lilly & Co Recent Developments
  31. 4.6 Gan & Lee
  32. 4.6.1 Gan & Lee Company Information
  33. 4.6.2 Gan & Lee Business Overview
  34. 4.6.3 Gan & Lee Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Gan & Lee Long-acting Insulin Injection Product Portfolio
  36. 4.6.5 Gan & Lee Recent Developments
  37. 4.7 Wockhardt
  38. 4.7.1 Wockhardt Company Information
  39. 4.7.2 Wockhardt Business Overview
  40. 4.7.3 Wockhardt Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Wockhardt Long-acting Insulin Injection Product Portfolio
  42. 4.7.5 Wockhardt Recent Developments
  43. 4.8 Viatris
  44. 4.8.1 Viatris Company Information
  45. 4.8.2 Viatris Business Overview
  46. 4.8.3 Viatris Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Viatris Long-acting Insulin Injection Product Portfolio
  48. 4.8.5 Viatris Recent Developments
  49. 4.9 Swixx Biopharma
  50. 4.9.1 Swixx Biopharma Company Information
  51. 4.9.2 Swixx Biopharma Business Overview
  52. 4.9.3 Swixx Biopharma Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Swixx Biopharma Long-acting Insulin Injection Product Portfolio
  54. 4.9.5 Swixx Biopharma Recent Developments
  55. 4.10 Lupin Laboratories
  56. 4.10.1 Lupin Laboratories Company Information
  57. 4.10.2 Lupin Laboratories Business Overview
  58. 4.10.3 Lupin Laboratories Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lupin Laboratories Long-acting Insulin Injection Product Portfolio
  60. 4.10.5 Lupin Laboratories Recent Developments
  61. 4.11 KALBE PHARMA
  62. 4.11.1 KALBE PHARMA Company Information
  63. 4.11.2 KALBE PHARMA Business Overview
  64. 4.11.3 KALBE PHARMA Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 KALBE PHARMA Long-acting Insulin Injection Product Portfolio
  66. 4.11.5 KALBE PHARMA Recent Developments
  67. 4.12 INFION PHARMA
  68. 4.12.1 INFION PHARMA Company Information
  69. 4.12.2 INFION PHARMA Business Overview
  70. 4.12.3 INFION PHARMA Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 INFION PHARMA Long-acting Insulin Injection Product Portfolio
  72. 4.12.5 INFION PHARMA Recent Developments
  73. 4.13 Cipla
  74. 4.13.1 Cipla Company Information
  75. 4.13.2 Cipla Business Overview
  76. 4.13.3 Cipla Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Cipla Long-acting Insulin Injection Product Portfolio
  78. 4.13.5 Cipla Recent Developments
  79. 4.14 Biocon Biologics
  80. 4.14.1 Biocon Biologics Company Information
  81. 4.14.2 Biocon Biologics Business Overview
  82. 4.14.3 Biocon Biologics Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Biocon Biologics Long-acting Insulin Injection Product Portfolio
  84. 4.14.5 Biocon Biologics Recent Developments
  85. 4.15 Biocare
  86. 4.15.1 Biocare Company Information
  87. 4.15.2 Biocare Business Overview
  88. 4.15.3 Biocare Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Biocare Long-acting Insulin Injection Product Portfolio
  90. 4.15.5 Biocare Recent Developments
  91. 4.16 Abbott Laboratories
  92. 4.16.1 Abbott Laboratories Company Information
  93. 4.16.2 Abbott Laboratories Business Overview
  94. 4.16.3 Abbott Laboratories Long-acting Insulin Injection Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Abbott Laboratories Long-acting Insulin Injection Product Portfolio
  96. 4.16.5 Abbott Laboratories Recent Developments
5 Global Long-acting Insulin Injection Market Scenario by Region
  1. 5.1 Global Long-acting Insulin Injection Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Long-acting Insulin Injection Sales by Region: 2021-2032
  3. 5.2.1 Global Long-acting Insulin Injection Sales by Region: 2021-2026
  4. 5.2.2 Global Long-acting Insulin Injection Sales by Region: 2027-2032
  5. 5.3 Global Long-acting Insulin Injection Revenue by Region: 2021-2032
  6. 5.3.1 Global Long-acting Insulin Injection Revenue by Region: 2021-2026
  7. 5.3.2 Global Long-acting Insulin Injection Revenue by Region: 2027-2032
  8. 5.4 North America Long-acting Insulin Injection Market Facts & Figures by Country
  9. 5.4.1 North America Long-acting Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Long-acting Insulin Injection Sales by Country (2021-2032)
  11. 5.4.3 North America Long-acting Insulin Injection Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Long-acting Insulin Injection Market Facts & Figures by Country
  16. 5.5.1 Europe Long-acting Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Long-acting Insulin Injection Sales by Country (2021-2032)
  18. 5.5.3 Europe Long-acting Insulin Injection Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Long-acting Insulin Injection Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Long-acting Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Long-acting Insulin Injection Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Long-acting Insulin Injection Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Long-acting Insulin Injection Market Facts & Figures by Country
  41. 5.7.1 South America Long-acting Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Long-acting Insulin Injection Sales by Country (2021-2032)
  43. 5.7.3 South America Long-acting Insulin Injection Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Long-acting Insulin Injection Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Long-acting Insulin Injection Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Long-acting Insulin Injection Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Long-acting Insulin Injection Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Long-acting Insulin Injection Sales by Type (2021-2032)
  2. 6.1.1 Global Long-acting Insulin Injection Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Long-acting Insulin Injection Sales Market Share by Type (2021-2032)
  4. 6.2 Global Long-acting Insulin Injection Revenue by Type (2021-2032)
  5. 6.2.1 Global Long-acting Insulin Injection Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Long-acting Insulin Injection Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Long-acting Insulin Injection Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Long-acting Insulin Injection Sales by Application (2021-2032)
  2. 7.1.1 Global Long-acting Insulin Injection Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Long-acting Insulin Injection Sales Market Share by Application (2021-2032)
  4. 7.2 Global Long-acting Insulin Injection Revenue by Application (2021-2032)
  5. 7.2.1 Global Long-acting Insulin Injection Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Long-acting Insulin Injection Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Long-acting Insulin Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Long-acting Insulin Injection Value Chain Analysis
  2. 8.1.1 Long-acting Insulin Injection Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Long-acting Insulin Injection Production Mode & Process
  5. 8.2 Long-acting Insulin Injection Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Long-acting Insulin Injection Distributors
  8. 8.2.3 Long-acting Insulin Injection Customers
9 Global Long-acting Insulin Injection Analyzing Market Dynamics
  1. 9.1 Long-acting Insulin Injection Industry Trends
  2. 9.2 Long-acting Insulin Injection Industry Drivers
  3. 9.3 Long-acting Insulin Injection Industry Opportunities and Challenges
  4. 9.4 Long-acting Insulin Injection Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst